|Other Names||WD repeat domain phosphoinositide-interacting protein 4, WIPI-4, WD repeat-containing protein 45, WDR45, WDRX1, WDRXI4, WIPI4|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13313a was selected from the N-term region of WDR45. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||WDRX1, WDRXI4, WIPI4|
|Function||Plays an important role in the autophagy pathway, which is the major intracellular degradation system by which cytoplasmic materials are packaged into autophagosomes and delivered to lysosomes for degradation.|
|Tissue Location||Ubiquitously expressed, with high expression in skeletal muscle and heart. Weakly expressed in liver and placenta. Expression is down-regulated in pancreatic and in kidney tumors.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the WD repeat proteinfamily. WD repeats are minimally conserved regions of approximately40 amino acids typically bracketed by gly-his and trp-asp (GH-WD),which may facilitate formation of heterotrimeric or multiproteincomplexes. Members of this family are involved in a variety ofcellular processes, including cell cycle progression, signaltransduction, apoptosis, and gene regulation. This gene has apseudogene at chromosome 4q31.3. Multiple alternatively splicedtranscript variants encoding distinct isoforms have been found forthis gene, but the biological validity and full-length nature ofsome variants have not been determined.
Proikas-Cezanne, T., et al. Oncogene 23(58):9314-9325(2004)Jeffries, T.R., et al. Mol. Biol. Cell 15(6):2652-2663(2004)Clark, A.G., et al. Science 302(5652):1960-1963(2003)
If you have any additional inquiries please email technical services at email@example.com.